


21/11/2024

Preliminary interim data as d	of September 30th, 2024	
TiGER Post Market Registry	Enrolled w/ TREO ®	330
10 Acric	Clínic Barcelona	UNIVERSITAT BARCELONA

In	dication for Treatr	nent (Site Rep	oorted)
		% (n/N)	
	Penetrating Atherosclerotic Ulcer (PAU)	2.7% (9/330)	
	Aortic Aneurysm	94.8% (313/330)	
	Fusiform	79.6% (215/270)	
	Saccular	20.4% (55/270)	
	Intramural Hematoma	0% (0/330)	
	Pseudoaneurysm	0.3% (1/330)	
	Unknown/Other	2.1% (7/330)	
TERUMO	Preliminary Data. Data may change. Data cut of 30 Sep 2024	Clínic Barcelona	BARGARINGIA



	Comorbic	lities (Site Reported)
		% (n/N) or Mean ± SD (n)
	Smoking History	
	Current Smoker	26.5% (87/328)
	Former Smoker	56.7% (186/328)
	Never Smoked	16.8% (55/328)
	ASA Grade	
	I	1.8% (1/329)
	II	18.8% (62/329)
	III	63.8% (210/329)
	IV	14.9% (49/329)
	V	0.6% (2/329)
	SVS/AAS Comorbidity Score	0.8 ± 0.5 (329)
14 Aortic		Data aut of 30 Sep 2024.

Medical History	
Type 2 Diabetes	% (n/N) 18.8% (62/330)
Previous Endovascular or Open Surgery	15.8 % (52/330)
Other Vascular interventions	14.5% (48/330)
History of Stroke	13.0% (43/330)
Current use of Antiplatelet/Anticoagulant medications	78.2% (258/330)
Chronic Obstructive Pulmonary Disorder (COPD)	18.8% (61/330)
Claudication	4.3% (14/330)
Hypercholesterolemia	36.9% (120/330)
Hyperlipidemia	25.2% (82/330)
Hypertension	76.0% (247/330)
Neurological Disease	7.1% (23/330)
Peripheral Vascular Disease	14.5 (47/330)
Renal Insufficiency	13.8% (45/330)
Coronary Artery Disease	40.3% (133/330)
Gastrointestinal Complications	4.2% (14/330)

	% (n/N) or Mean ± SD (n)	Range
Surgical Acuity		
Flective	94.5% (312/330)	
Emergent	5.5% (18/330)	
Anesthesia Type		
General Anesthesia	72.1% (238/330)	
 Local Anesthesia 	26.1% (86/330)	
Other	1.8% (6/330)	
Mean Hospital Stay (days)	5.3± 4.7 (327)	1 - 35
Mean ICU Stay (hours)	6.9 ± 20.6 (326)	0 - 175
Total Surgery Time (min)	105.5 ± 48.3 (330)	0 - 298
Total Endovascular Time (min)	87.1 ± 39.1 (275)	3 - 298
Estimated Blood Loss (mL)	140.4 ± 186.6 (197)	0 - 1100
Transfusion Required	22.7% (75/330)	
Vascular Access		
Cut Down	10.6% (35/330)	
 Percutaneous 	89.1% (294/330)	
Conduit	0.3% (1/330)	
Discharge Destination		
 Temporary Ambulatory Care Center 	0.3% (1/327)	
 Return to pre-op living location 	97.6% (319/327)	
Other	2.1% (7/327)	

	% (n/N)
ponents of Technical Success	
Device introduction into the entry site acceptable	100% (327/327)
Advancement of device to the lesion site acceptable	99.4% (325/327) 100% Acceptal
Device deployment from the delivery system acceptable	100.0% (327/327) / Device
Accuracy of the device system deployment acceptable	Introduce
Stent-graft patent	100.0% (327/327) Deployme 100.0% (327/327) Accuracy 2000 (327/327) Poto
Device integrity maintained (no tears, fractures, etc.)	
 Stent-graft deployed without kinking or twisting 	99.1% (324/327)
 Absence of Type Ia, Type Ib, Type IIIa and Type IIIb en 	doleak 98.8% (326/330)

	M	lorta	lity (Sir	e Reported)			
	Procedure (POD 0 - POD 29)	Early Follow-up	12 Months	2 Years	3 Years	4 Years	Total (subjects)
Visits Performed	330	212	191	106	38	5	330
All-Cause Mortality	0.9% (3/330)	1.4% (3/212)	5.2% (10/191)	3.8% (4/106)	7.9% (3/38)	40% (2/5)	7.6% (25/330)
Aortic-Related Mortality	0.9% (3/330)	0.5% (1/212)	0	0	0	0	1.2% (4/330)
Aortic Related Death (n=4) Definitor: Artic-related death interdet to text the target lesio Subject 012-043 (Subject 012-003 failed Subject 001-004 (Subject 002-012 (POD 3), Microemb (POD 3), Due to POD 16), Complic	olization myocardial inf ated kidney cys	arction Impella			repo	Aortic- related ortality was rted as ce or
18 Aortic			nge. Data cut of 30 :	iep 2024.	Clínic Barcelo		BARCELON

E	Indo	leaks	(Site Rep	orted)		
	Early Follow-up	12 Months	2 Years	3 Years	Total (subjects)	
Subjects w/ Adequate Imaging*	189	160	89	33	330	
Total Type I & Type III	2.1% (4/189)	1.3% (2/160)	3.3% (3/89)	3.0% (1/33)	<mark>3.0% (</mark> 10/330)	
Type Ia			,			
New	1.1% (2/189)	0	0	3.0% (1/33)	0.9% (3/330)	
Type Ib						
New	0.5% (1/189)	1.3% (2/160)	1.1% (1/89)	0	1.2% (4/330)	
Type III						
New	0.5% (1/189)	0	2.2% (2/89)	0	0.9% (3/330)	
TERUMO 19 Aortic Prelin	ainary Data. Data n	nay change. Data cut	of 30 Sep 2024.			CELC

	Early Follow-up	12 Months	2 Years	3 Years
Subjects w/ Adequate Imaging	195	169	97	33
Patent Stent-Graft	98.0% (191/195)	97.0% (164/169)	95.9% (93/97)	100% (33/33)
Limb Occlusions				
New	<mark>2.1% (4/195)</mark>	2.4% (4/169)	4.1% (4/97)	0
Persistent	0	0.6% (1/169)	0	0
Kinking	<mark>0</mark>	O	O	0

	Early Follow-up	12 Months	2 Years
Subjects w/ Adequate Imaging	189	138	82
Increase > 5mm			
New	NA	3.6% (5/138)	1.2% (1/82)
Persistent	NA	0	0
Decrease	NA	43.5% (60/138)	30.5% (25/82)
Stable	NA	52.9% (73/138)	68.3% (56/82)

